BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 9626197)

  • 1. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience--a pediatric oncology group study.
    Katzenstein HM; Bowman LC; Brodeur GM; Thorner PS; Joshi VV; Smith EI; Look AT; Rowe ST; Nash MB; Holbrook T; Alvarado C; Rao PV; Castleberry RP; Cohn SL
    J Clin Oncol; 1998 Jun; 16(6):2007-17. PubMed ID: 9626197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
    George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
    J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study.
    Alvarado CS; London WB; Look AT; Brodeur GM; Altmiller DH; Thorner PS; Joshi VV; Rowe ST; Nash MB; Smith EI; Castleberry RP; Cohn SL
    J Pediatr Hematol Oncol; 2000; 22(3):197-205. PubMed ID: 10864050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
    Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
    J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYCN expression is not prognostic of adverse outcome in advanced-stage neuroblastoma with nonamplified MYCN.
    Cohn SL; London WB; Huang D; Katzenstein HM; Salwen HR; Reinhart T; Madafiglio J; Marshall GM; Norris MD; Haber M
    J Clin Oncol; 2000 Nov; 18(21):3604-13. PubMed ID: 11054433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-Myc gene amplification is a major prognostic factor in localized neuroblastoma: results of the French NBL 90 study. Neuroblastoma Study Group of the Société Francaise d'Oncologie Pédiatrique.
    Rubie H; Hartmann O; Michon J; Frappaz D; Coze C; Chastagner P; Baranzelli MC; Plantaz D; Avet-Loiseau H; Bénard J; Delattre O; Favrot M; Peyroulet MC; Thyss A; Perel Y; Bergeron C; Courbon-Collet B; Vannier JP; Lemerle J; Sommelet D
    J Clin Oncol; 1997 Mar; 15(3):1171-82. PubMed ID: 9060561
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group.
    Goto S; Umehara S; Gerbing RB; Stram DO; Brodeur GM; Seeger RC; Lukens JN; Matthay KK; Shimada H
    Cancer; 2001 Nov; 92(10):2699-708. PubMed ID: 11745206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.
    Schmidt ML; Lukens JN; Seeger RC; Brodeur GM; Shimada H; Gerbing RB; Stram DO; Perez C; Haase GM; Matthay KK
    J Clin Oncol; 2000 Mar; 18(6):1260-8. PubMed ID: 10715296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse outcome of infants with metastatic neuroblastoma, MYCN amplification and/or bone lesions: results of the French society of pediatric oncology.
    Minard V; Hartmann O; Peyroulet MC; Michon J; Coze C; Defachelle AS; Lejars O; Perel Y; Bergeron C; Boutard P; Leverger G; Stephan JL; Thyss A; Chastagner P; Couillault G; Devalck C; Lutz P; Mechinaud F; Millot F; Plantaz D; Rialland X; Rubie H
    Br J Cancer; 2000 Oct; 83(8):973-9. PubMed ID: 10993641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical relevance of tumor cell ploidy and N-myc gene amplification in childhood neuroblastoma: a Pediatric Oncology Group study.
    Look AT; Hayes FA; Shuster JJ; Douglass EC; Castleberry RP; Bowman LC; Smith EI; Brodeur GM
    J Clin Oncol; 1991 Apr; 9(4):581-91. PubMed ID: 2066755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database.
    Bagatell R; Beck-Popovic M; London WB; Zhang Y; Pearson AD; Matthay KK; Monclair T; Ambros PF; Cohn SL;
    J Clin Oncol; 2009 Jan; 27(3):365-70. PubMed ID: 19047282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.
    Twist CJ; Naranjo A; Schmidt ML; Tenney SC; Cohn SL; Meany HJ; Mattei P; Adkins ES; Shimada H; London WB; Park JR; Matthay KK; Maris JM
    J Clin Oncol; 2019 Jan; 37(2):115-124. PubMed ID: 30444686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management and outcome of stage 3 neuroblastoma.
    Modak S; Kushner BH; LaQuaglia MP; Kramer K; Cheung NK
    Eur J Cancer; 2009 Jan; 45(1):90-8. PubMed ID: 18996003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children's cancer group study.
    Perez CA; Matthay KK; Atkinson JB; Seeger RC; Shimada H; Haase GM; Stram DO; Gerbing RB; Lukens JN
    J Clin Oncol; 2000 Jan; 18(1):18-26. PubMed ID: 10623689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver involvement in neuroblastoma: the Memorial Sloan-Kettering Experience supports treatment reduction in young patients.
    Kushner BH; Kramer K; LaQuaglia MP; Modak S; Cheung NK
    Pediatr Blood Cancer; 2006 Mar; 46(3):278-84. PubMed ID: 16124002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neuroblastoma in adolescents: the Italian experience.
    Conte M; Parodi S; De Bernardi B; Milanaccio C; Mazzocco K; Angelini P; Viscardi E; Di Cataldo A; Luksch R; Haupt R
    Cancer; 2006 Mar; 106(6):1409-17. PubMed ID: 16475209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The impact of surgical radicality on outcome in childhood neuroblastoma.
    von Schweinitz D; Hero B; Berthold F
    Eur J Pediatr Surg; 2002 Dec; 12(6):402-9. PubMed ID: 12548494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study.
    Bowman LC; Castleberry RP; Cantor A; Joshi V; Cohn SL; Smith EI; Yu A; Brodeur GM; Hayes FA; Look AT
    J Natl Cancer Inst; 1997 Mar; 89(5):373-80. PubMed ID: 9060959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy.
    Bagatell R; Rumcheva P; London WB; Cohn SL; Look AT; Brodeur GM; Frantz C; Joshi V; Thorner P; Rao PV; Castleberry R; Bowman LC
    J Clin Oncol; 2005 Dec; 23(34):8819-27. PubMed ID: 16314642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
    Hu HL; He LJ
    Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.